TAXOTERE Drug Patent Profile

Which patents cover Taxotere, and when can generic versions of Taxotere launch?

Taxotere is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in TAXOTERE is docetaxel. There are forty-one drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the docetaxel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Taxotere

A generic version of TAXOTERE was approved as docetaxel by HOSPIRA INC on March 8^th, 2011.

Summary for TAXOTERE

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for TAXOTERE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAXOTERE	Injection	docetaxel	40 mg/mL, 0.5 mL and 2 mL vials	020449	1	2009-06-30

US Patents and Regulatory Information for TAXOTERE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-003	Aug 3, 2010		DISCN	Yes	No
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-005	Apr 13, 2012	AP	RX	Yes	No
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996		DISCN	Yes	No
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-004	Aug 2, 2010		DISCN	Yes	No

International Patents for TAXOTERE

See the table below for patents covering TAXOTERE around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	217839	Eljárások taxánszármazékokat tartalmazó új stabil gyógyszerkészítmények előállítására (NOVEL METHODS FOR PRODUCING STABILE MEDICAMENTS CONTAINING TAXANE DERIVATIVES)
Finland	952680
Greece	3025714
Australia	666859
Japan	H0651689

Supplementary Protection Certificates for TAXOTERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1667986	28/2013	Austria		PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
0253738	96C0009	Belgium		PRODUCT NAME: CONCENTRE A 85 % D'OMEGA POLYINSATURES; QUANTITE CORRESPONDANT A :; ESTERS ETHYLIQUES D'ACIDE EICOSAPENTAENOIQUE (EPA) ET D'ACIDE DOCOSAHEXAENOIQUE (DHA); ALPHA TOCOPHEROL; NAT. REGISTRATION NO/DATE: NL 20819 19951002; FIRST REGISTRATION:
0253738	C960002	Netherlands		PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127

Investment Scenario, Market Dynamics, and Financial Trajectory for TAXOTERE (Docetaxel)

Last updated: February 3, 2026

Executive Summary

TAXOTERE (docetaxel) is a chemotherapeutic agent developed by Sanofi, primarily used to treat various cancers including breast, non-small cell lung, prostate, stomach, and head and neck cancers. As of 2023, its market landscape faces significant shifts due to patent expirations, emerging biosimilars, regulatory challenges, and evolving treatment guidelines.

The drug's financial trajectory depends heavily on patent protections, market penetration, competition from generics, and the strategic responses of the manufacturer. Investment opportunities hinge on factors like patent expiry timelines, pipeline developments, and changing oncology treatment protocols.

This report provides a comprehensive analysis of TAXOTERE’s current market position, future market dynamics, competitive landscape, and key financial indicators, enabling informed investment decisions.

---

Overview of TAXOTERE (Docetaxel)

Attribute	Details
Brand Name	TAXOTERE
Generic Name	Docetaxel
Therapeutic Class	Antineoplastic/chemotherapy agent
Approved Indications	Breast, non-small cell lung, prostate, gastric, head and neck cancers
Manufacturer	Sanofi
Approval Date	1995 (initial approval), with various extensions and patents
Formulation	Intravenous infusion
Patents and Exclusivities	Patent protection until 2018 (U.S. and EU), with extensions in certain markets

---

Market Dynamics

1. Patent Expirations and Generic Entry

Year	Key Event	Impact
2018	Patent expiry in major markets (e.g., U.S., EU)	Surge in generic competition, price erosion
2018-2023	Increased penetration by biosimilars and generic versions	Declining revenue, market share erosion

Note: Patent expirations have typically resulted in >60% price declines within two years post-generic entry, according to IQVIA data.

---

2. Competition from Biosimilars and Generics

Competitor(s)	Market Entry Year	Market Share Impact	Pricing Pressure
Teva, Sun Pharma, Sandoz	2018-2020	Significant in US/EU	30-50% discounts vs. branded
Emerging biosimilar candidates	2022–2023	Growing, especially in Europe	Further erosion on margins

Note: Biosimilar adoption is slower due to regulatory and reimbursement hurdles but gaining momentum, especially in Europe.

---

3. Regulatory and Reimbursement Policies

Region	Policy Highlights	Impact
US	FDA approved biosimilars; CMS reimbursement policies	Reduced perceived value of branded TAXOTERE
EU	EMA approves biosimilars; national reimbursement strategies	Growing biosimilar uptake, shrinking market share

The regulatory environment increasingly favors biosimilars, pressuring brand-name oncologic drugs.

---

4. Clinical and Treatment Paradigm Evolution

Shifts	Effect
Development of targeted therapies and immuno-oncology agents	Reduces reliance on traditional chemotherapies like TAXOTERE
Shift towards personalized medicine	Limits broad-spectrum chemotherapy usage, affecting volumes
Adoption of combination therapies with novel agents	May decrease TAXOTERE utilization as monotherapy or in combinations

---

Financial Trajectory and Revenue Projections

1. Historical Revenue and Sales Data

Year	Estimated Global Sales (USD millions)	Notes
2015	$2.5 billion	Peak sales pre-patent expiry
2018	$1.2 billion	Post-patent expiry, generic entry
2020	$0.8 billion	Further decline, regional variations
2022	$0.6 billion	Stabilization with biosimilar competition

Note: Figures are approximate and sourced from IQVIA and company financial reports.

---

2. Revenue Forecasts (2023-2028)

Year	US$ Millions	Assumptions
2023	$0.55 billion	Industry-wide generic/gaps in biosimilar adoption continues
2024	$0.50 billion	Slight decline as biosimilar market penetrates further
2025	$0.45 billion	Persistent price erosion; growth of biosimilars in major markets
2026	$0.42 billion	Market stabilization with evolving treatment pathways
2028	$0.38 billion	Continuing decline with shift toward targeted therapies

Note: These projections are sensitive to regulatory changes, biosimilar uptake, and the development of new therapies.

---

Investment Considerations

1. Patent and Market Protection Timeline

Timeline	Key Event	Strategic Implication
Until 2018	Patent protections active	Revenue stability; premium pricing
2018 onwards	Patent expiry, generic/biosimilar entry	Revenue erosion; need for pipeline diversification

2. Pipeline and Lifecycle Strategy

QC	Strategy Focus
Diversification	Developing or acquiring novel chemotherapy agents, immuno-oncology therapies
Lifecycle Management	Formulation improvements, combination regimens, marker-driven use

Sanofi's pipeline includes agents targeting other cancers, but no direct follow-on for TAXOTERE’s core indications is publicly confirmed.

3. Licensing, Mergers, and Acquisitions

Activity Type	Trends	Effect on Investment Outlook
Mergers & Acquisitions	Oncology drug pipeline consolidation, biosimilar acquisitions	Potential value increase through diversification
Licensing Deals	Partnerships with biotech firms for new chemotherapies/biologics	Access to innovation, mitigating patent cliffs

---

Comparison with Competing Oncology Drugs

Drug/Agent	Approval Year	Core Indications	Market Share (2022)	Price Trends
TAXOTERE (docetaxel)	1995	Breast, lung, prostate	~30% in chemotherapy segment	Declining post-generic entry
Taxanes (Generic paclitaxel)	1960s, generics post-2000s	Broad cancer indications	Dominant, lower prices	Price reductions, high volume
Abraxane (paclitaxel albumin-bound)	2005	Breast, lung, pancreatic	Growing, premium pricing	Higher cost, targeted therapy benefit
Immunotherapies (e.g., Pembrolizumab)	2014	Multiple cancers	Increasing share	Growing, potentially replacing chemotherapies

---

Market Opportunities and Risks

Opportunities	Risks
Expansion into emerging markets with favorable prices	Substitution by targeted therapies and immuno-oncology agents
Development of combination regimens	Accelerated biosimilar competition
Lifecycle extensions via new formulations or indications	Declining relevance as clinicians shift toward personalized therapies
Strategic alliances and licensing	Regulatory hurdles and reimbursement challenges

---

Regulatory Policies and Market Access

Region	Policies Impacting TAXOTERE	Effect
US	FDA biosimilar pathway, CMS reimbursement	Increasing biosimilar market share, reducing revenue from branded TAXOTERE
EU	EMA biosimilar approvals, national health policies	Market share shift towards biosimilars, pressure on pricing
Asia	Varying policies, rapidly growing oncology markets	Potential growth, contingent on local approvals and prices

---

Key Financial Metrics & Valuation Indicators

Metric	2022 Estimate	Rationale
Market Share	~25-30% (chemotherapy segment)	Post-generic erosion
Price per Unit	Approx. $200–$350 (depending on region)	Declined since patent expiry
Revenue (global)	~$600 million	Reflecting erosion but remaining significant
Gross Margin	~70% (brand-branded)	Likely decreased due to cheaper biosimilars
R&D Investment	In decline, focus on pipeline licensing, biologics	Strategic shift

---

Conclusion

TAXOTERE’s market prospects face mounting challenges from patent expirations, biosimilar and generic competition, and shifting treatment paradigms favoring targeted and immunotherapies. While still generating meaningful revenue, its financial trajectory indicates a decline unless mitigated by pipeline innovations or lifecycle management strategies.

Investors should weigh the residual value of its global market share against the risk of continued erosion. Opportunities exist for licensing, pipeline development, or entering emerging markets, but significant downside risks are linked to rapid biosimilar adoption and changing clinical practices.

---

Key Takeaways

• Patent expiration in 2018 led to a sharp decline in sales globally; ongoing erosion continues due to biosimilar competition.
• Market share decline is accelerated by the introduction of biosimilars like Sandoz’s and Teva’s versions; price reductions average 30-50% post-generic entry.
• Regulatory push for biosimilars in US and EU further pressures branded revenue streams.
• Treatment shifts toward target therapy and immunotherapy reduce reliance on traditional chemotherapies like TAXOTERE.
• Future revenue estimated to decline steadily through 2028, with forecasts around $380–$450 million annually for the foreseeable future.
• Strategic opportunities include pipeline expansion, pipeline licensing, and focus on emerging markets; risks primarily include accelerated biosimilar adoption and decreased clinical reliance.

---

FAQs

Q1: When does the patent for TAXOTERE expire, and what are the implications?
A1: The primary patents expired around 2018 in major markets like the US and EU. This led to a surge in biosimilar and generic competition, significantly reducing pricing and revenues.

Q2: How do biosimilars impact the value of TAXOTERE?
A2: Biosimilars compete directly with branded TAXOTERE, offering comparable efficacy at lower prices, resulting in substantial market share loss and revenue decline for Sanofi.

Q3: Are there any new formulations or indications that could extend TAXOTERE’s market life?
A3: No published new formulations or indications are confirmed; lifecycle extensions primarily depend on pipeline development or combination strategies.

Q4: How does the shift to targeted therapies affect the chemotherapy market?
A4: The rise of personalized medicine and immunotherapies reduces reliance on broad-spectrum chemotherapies like TAXOTERE, contributing to its declining market share.

Q5: What strategic moves should investors monitor concerning TAXOTERE?
A5: Watch for pipeline licensing deals, biosimilar acceptance rates, regulatory approvals in emerging markets, and any lifecycle extension initiatives.

---

Sources

[1] IQVIA. (2022). Global Oncology Market Analysis.
[2] Sanofi. (2022). Annual Financial Report.
[3] FDA. (2022). Biosimilar Drug Approvals and Pathways.
[4] European Medicines Agency. (2022). Biosimilar Guidelines.
[5] MarketWatch. (2023). Oncology Drug Market Trends.